Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRX-4TZT transdermal tizanidine versus oral tizanidine in multiple sclerosis spasticity
ACTRN12626000112369Phase 2Recruiting
- Sponsor
- MEDRx
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MRX-4TZT and tizanidine in multiple sclerosis (MS) (4 arms), sponsored by MEDRx. Primary endpoints: Safety of MRX-4TZT and oral tizanidine and Tolerability of MRX-4TZT and oral tizanidine. Started May 2026; status: recruiting.
02
Drugs
MRX-4TZTtizanidine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ACTRN12626000112369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000112369.